# Future Improvements — Production-Ready Roadmap

This document outlines the enhancements required to evolve the Deprescribing CDSS from a functional prototype into a **production-grade, HIPAA-eligible, revenue-generating clinical decision support platform**. Each section is organized by domain with estimated effort, priority, and rationale.

---

## Table of Contents

- [1. Infrastructure & DevOps](#1-infrastructure--devops)
- [2. Backend Engineering](#2-backend-engineering)
- [3. Frontend Engineering](#3-frontend-engineering)
- [4. Clinical & Data Completeness](#4-clinical--data-completeness)
- [5. Security & Compliance](#5-security--compliance)
- [6. AI & Intelligence](#6-ai--intelligence)
- [7. Monetization Strategy](#7-monetization-strategy)
- [8. UX & Adoption](#8-ux--adoption)
- [9. EHR Integration](#9-ehr-integration)
- [10. Analytics & Population Health](#10-analytics--population-health)
- [11. Internationalization & Localization](#11-internationalization--localization)
- [12. Performance & Scalability](#12-performance--scalability)
- [Priority Matrix](#priority-matrix)

---

## 1. Infrastructure & DevOps

| # | Improvement | Effort | Priority | Rationale |
|---|-------------|--------|----------|-----------|
| 1.1 | **Docker containerization** — Dockerfile for backend, Dockerfile for frontend, `docker-compose.yml` orchestrating both services | 2 days | **Critical** | Eliminates "works on my machine"; standardizes deployment across dev/staging/prod |
| 1.2 | **CI/CD pipeline** — GitHub Actions for linting, testing, building, and deploying to staging/production | 2 days | **Critical** | Automates quality gates; prevents regressions; enables rapid iteration |
| 1.3 | **Infrastructure as Code** — Terraform/Pulumi scripts for cloud deployment (AWS ECS, Google Cloud Run, or Azure App Service) | 3 days | High | Reproducible, auditable infrastructure; enables disaster recovery |
| 1.4 | **Environment-specific configuration** — Dev/staging/prod `.env` management with secrets vault (AWS Secrets Manager / HashiCorp Vault) | 1 day | **Critical** | Prevents accidental credential exposure; enables safe multi-environment deployments |
| 1.5 | **Database migration** — Migrate from CSV datasets to a proper relational database (PostgreSQL) with Alembic migrations | 5 days | High | Enables transactional integrity, concurrent writes, and proper querying; CSVs are not suitable for concurrent production access |
| 1.6 | **Reverse proxy & load balancing** — Nginx/Traefik for SSL termination, rate limiting, and load balancing across multiple backend instances | 1 day | High | Required for production traffic; enables zero-downtime deployments |
| 1.7 | **Health check & monitoring** — Prometheus metrics endpoint + Grafana dashboards for API latency, error rates, and system resources | 2 days | High | Observability is essential for production incident response |
| 1.8 | **Structured logging** — Replace `print()` statements with structured logging (Loguru or structlog) shipping to ELK/Loki | 1 day | Medium | Enables log aggregation, search, and alerting |
| 1.9 | **Sentry/APM integration** — Error tracking (Sentry) and application performance monitoring (Datadog/New Relic) | 1 day | Medium | Proactive error detection and performance bottleneck identification |

---

## 2. Backend Engineering

| # | Improvement | Effort | Priority | Rationale |
|---|-------------|--------|----------|-----------|
| 2.1 | **Comprehensive test suite** — pytest with unit tests for every engine, integration tests for endpoints, property-based tests for clinical rules | 5 days | **Critical** | Current code has zero automated backend tests; critical for clinical safety validation |
| 2.2 | **Background task processing** — Move AI-heavy endpoints (prescription parsing, taper plan generation) to Celery/Redis task queues with WebSocket status updates | 4 days | High | Gemini API calls can take 5-30s; synchronous requests block the API server and timeout |
| 2.3 | **Request caching** — Implement Redis caching for frequently queried data (drug lists, herb lists, common interaction checks) | 2 days | Medium | Reduces latency for reference data; lowers Gemini API costs |
| 2.4 | **Input validation hardening** — Comprehensive Pydantic validators for clinical ranges (age 0-120, eGFR 0-200, realistic dose ranges) | 1 day | Medium | Prevents nonsensical inputs from producing misleading clinical output |
| 2.5 | **API versioning** — Prefix endpoints with `/v1/` to allow backward-compatible API evolution | 1 day | Medium | Enables gradual client migration as the API evolves |
| 2.6 | **Endpoint response standardization** — Wrap all responses in a consistent envelope (`{"success": true, "data": ..., "error": null}`) | 1 day | Medium | Consistent client-side error handling; simplifies SDK generation |
| 2.7 | **Rate limiting** — Implement `slowapi` or middleware-based rate limiting per client IP/API key | 1 day | Medium | Prevents abuse; required for paid API tiers |
| 2.8 | **Webhook notifications** — Allow clients to register webhooks for asynchronous analysis completion | 3 days | Low | Enables integration with EHR systems that need async workflows |
| 2.9 | **Bulk analysis endpoint** — `/analyze-patients/bulk` accepting a CSV/JSON array of patients for batch processing | 2 days | Low | Useful for nursing homes processing all residents quarterly |
| 2.10 | **Audit logging** — Log every clinical analysis with immutable audit trail (who, what, when, result) | 2 days | **Critical** | Required for HIPAA compliance; essential for medico-legal defensibility |
| 2.11 | **Database-backed datasets** — Store all clinical rules in database tables with update timestamps and versioning | 3 days | High | Enables dataset updates without code redeployment; tracks which version of criteria was used for each analysis |

---

## 3. Frontend Engineering

| # | Improvement | Effort | Priority | Rationale |
|---|-------------|--------|----------|-----------|
| 3.1 | **React Router integration** — Add proper client-side routing (patient list, analysis results, history, settings) | 2 days | High | Current single-page approach limits navigation and deep-linking |
| 3.2 | **State management** — Adopt Redux Toolkit or Zustand for global state management | 2 days | Medium | Current `useState` approach doesn't scale; props drilling across deeply nested components is already visible |
| 3.3 | **TypeScript migration** — Convert `.jsx` to `.tsx` with proper type definitions for all API responses | 5 days | High | Catches type errors at compile time; improved developer experience and IDE support |
| 3.4 | **Component library** — Build a reusable design system (Button, Card, Modal, Table, FormField) using Tailwind + Headless UI primitives | 3 days | Medium | Ensures UI consistency; speeds up future feature development |
| 3.5 | **Responsive design audit** — Ensure full mobile/tablet responsiveness for bedside/laptop use | 2 days | Medium | Clinicians frequently use tablets; current layout is desktop-only |
| 3.6 | **Offline capability** — Implement service worker + IndexedDB for basic offline operation with sync-on-reconnect | 5 days | Low | Useful in hospitals with intermittent connectivity |
| 3.7 | **Accessibility (a11y)** — WCAG 2.1 AA compliance audit and remediation (keyboard navigation, screen readers, color contrast) | 3 days | Medium | Legal requirement for healthcare software in many jurisdictions |
| 3.8 | **Dark mode** — Tailwind-based dark mode toggle | 1 day | Low | User preference; reduces eye strain for long sessions |
| 3.9 | **Progressive Web App (PWA)** — manifest.json, service worker, install prompt | 2 days | Low | Enables "install to home screen"; reduces dependency on browser |
| 3.10 | **E2E testing** — Playwright or Cypress tests covering critical user workflows | 3 days | High | Ensures UI reliability during refactoring |

---

## 4. Clinical & Data Completeness

| # | Improvement | Effort | Priority | Rationale |
|---|-------------|--------|----------|-----------|
| 4.1 | **Drug database expansion** — Integrate RxNorm or NLM drug API for comprehensive medication coverage | 5 days | **Critical** | Current datasets are limited to ~100 drugs; production requires coverage of 1000+ medications |
| 4.2 | **NDC/RxCUI lookup** — Map medications to National Drug Code (NDC) and RxNorm Concept Unique Identifier (RxCUI) | 3 days | High | Enables interoperability with EHR systems; auto-populates brand/generic mappings |
| 4.3 | **Disease-drug interaction checking** — Add engine for drug-condition interactions (e.g., NSAIDs in CKD, beta-blockers in asthma) | 4 days | High | Current STOPP engine handles some disease-drug pairs, but coverage is limited |
| 4.4 | **Drug-drug interaction database** — Add comprehensive DDI checking using openFDA or DrugBank data | 5 days | High | Currently only handles herb-drug interactions; drug-drug interactions are a core CDSS requirement |
| 4.5 | **Renal dosing engine** — Add automatic dose adjustment recommendations for renal impairment (based on eGFR) | 3 days | High | Most hospitalized older adults have CKD; dose adjustment is a critical safety feature |
| 4.6 | **Hepatic dosing engine** — Add dose adjustment recommendations for hepatic impairment (Child-Pugh based) | 2 days | Medium | Important for patients with liver disease |
| 4.7 | **Pregnancy/lactation safety** — Add FDA pregnancy category and lactation safety checks | 2 days | Medium | Needed for women of childbearing age |
| 4.8 | **Drug-allergy checking** — Allow input of patient allergies and cross-reference with prescribed medications | 2 days | High | Basic safety check expected in any CDSS |
| 4.9 | **Clinical guideline versioning** — Tag each analysis with the version of Beers/STOPP/START criteria used | 1 day | Medium | As guidelines update every 3-5 years, knowing which version was used for a given analysis is important |
| 4.10 | **Medication reconciliation** — Allow comparison of current medications against previous analysis or hospital discharge summary | 3 days | Low | Useful for transitions of care |
| 4.11 | **Drug cost data** — Integrate with drug pricing APIs to include cost information in deprescribing recommendations | 3 days | Low | Cost is a major factor in medication adherence |

---

## 5. Security & Compliance

| # | Improvement | Effort | Priority | Rationale |
|---|-------------|--------|----------|-----------|
| 5.1 | **Authentication system** — JWT-based auth with OAuth2/OpenID Connect support (Auth0, Okta, or Azure AD) | 3 days | **Critical** | No authentication currently; every analysis has PHI implications |
| 5.2 | **Role-based access control (RBAC)** — Admin, Prescriber, Pharmacist, Read-only roles with granular permissions | 2 days | **Critical** | Different roles need different access levels; essential for enterprise deployment |
| 5.3 | **HIPAA compliance framework** — BAA-ready architecture with PHI encryption at rest and in transit, access logs, audit trails, automatic session timeout | 5 days | **Critical** | Required for any healthcare deployment in the US |
| 5.4 | **GDPR compliance** — Data minimization, right to deletion, right to export | 3 days | High | Required for EU market |
| 5.5 | **Data encryption** — AES-256 encryption for stored PHI; TLS 1.3 for all network traffic | 2 days | **Critical** | Baseline requirement for any healthcare data |
| 5.6 | **API key management** — Generate, rotate, and revoke API keys with usage quotas | 2 days | High | Required for monetization via API subscriptions |
| 5.7 | **Penetration testing** — Regular security audit and penetration testing | Ongoing | High | Required for SOC 2 / HITRUST certification |
| 5.8 | **Data retention policies** — Configurable auto-deletion of patient data after defined periods | 1 day | Medium | Compliance requirement; reduces breach risk |
| 5.9 | **Security headers** — CSP, HSTS, X-Frame-Options, X-Content-Type-Options in production | 1 day | Medium | Prevents common web vulnerabilities (XSS, clickjacking) |
| 5.10 | **GDPR-compliant AI data handling** — Ensure no PHI is sent to Gemini API; anonymize before AI calls | 2 days | **Critical** | Current code sends medication names to Gemini; needs local anonymization layer |

---

## 6. AI & Intelligence

| # | Improvement | Effort | Priority | Rationale |
|---|-------------|--------|----------|-----------|
| 6.1 | **Local ML model for taper plans** — Fine-tune a small LLM (Llama 3.1 8B or Mistral 7B) for taper plan generation, eliminating Gemini dependency for this task | 10 days | High | Reduces API costs (free → self-hosted); eliminates PHI transmission to third party |
| 6.2 | **AI confidence scoring** — Return confidence scores for all AI-generated recommendations | 2 days | Medium | Clinicians need to know when to trust vs. verify AI output |
| 6.3 | **Explainable AI (XAI)** — Provide plain-English reasoning traces for AI decisions | 3 days | Medium | Regulatory requirement in EU AI Act; builds clinician trust |
| 6.4 | **Clinical NLP pipeline** — Extract structured data from free-text clinical notes (chief complaint, diagnoses, medications) | 5 days | Medium | Enables analysis directly from clinical notes without manual data entry |
| 6.5 | **Personalized tapering with patient history** — Train a model to predict deprescribing success based on patient demographics and prior attempts | 10 days | Low | High-value feature for chronic medication management |
| 6.6 | **Fallback AI provider** — Support multiple AI providers (OpenAI, Claude, local models) with automatic failover | 2 days | High | Eliminates single point of failure; cost optimization |

---

## 7. Monetization Strategy

| Tier | Price (Monthly) | Features | Target Customer |
|------|-----------------|----------|-----------------|
| **Free** | $0 | 5 analyses/month, basic reports, herb-drug checker | Individual clinicians, residents |
| **Professional** | $49/user | Unlimited analyses, AI taper plans, PDF reports, priority support | Independent physicians, pharmacists |
| **Clinic** | $299/10 users | All Professional features + patient history tracking, bulk analysis, EHR integration | Primary care clinics, LTC facilities |
| **Enterprise** | Custom | All features + on-premise deployment, SSO, audit logs, SLA, dedicated support | Hospital systems, health networks |
| **API** | Per-call pricing | $0.10/analysis, $0.05/interaction check, volume discounts | EHR vendors, HIT developers |
| **White Label** | Custom | Full branding replacement, dedicated infrastructure, source code access | Large health systems, government health departments |

### Monetization Enablers

| # | Improvement | Effort | Priority |
|---|-------------|--------|----------|
| 7.1 | **Billing integration** — Stripe Billing or Chargebee for subscription management, invoicing, and metered API billing | 5 days | **Critical** |
| 7.2 | **Usage tracking** — Track per-user/per-tenant API usage with daily/monthly quotas | 2 days | **Critical** |
| 7.3 | **Tenant isolation** — Multi-tenant database architecture (schema-per-tenant or row-level security) | 5 days | **Critical** |
| 7.4 | **Free trial flow** — 14-day free trial with automatic downgrade | 2 days | High |
| 7.5 | **Landing page** — Marketing website with feature showcase, pricing table, and signup flow | 3 days | High |
| 7.6 | **Usage analytics dashboard** — Admin panel showing active users, analysis counts, API usage trends | 3 days | High |
| 7.7 | **Self-service portal** — Account management, API key generation, billing history, usage charts | 5 days | Medium |

---

## 8. UX & Adoption

| # | Improvement | Effort | Priority | Rationale |
|---|-------------|--------|----------|-----------|
| 8.1 | **Patient management dashboard** — List of patients with past analyses, comparison views, filtering/search | 4 days | High | Clinicians manage panels of patients, not one-off analyses |
| 8.2 | **Medication interaction visualizer** — Interactive network graph showing all drug-drug, drug-herb interactions | 3 days | Medium | Visual representation is more intuitive than text tables |
| 8.3 | **Clinical summary print view** — Printer-friendly, one-page clinical summary optimized for paper charts | 1 day | Medium | Many clinicians still use paper for rounds |
| 8.4 | **Medication history timeline** — Gantt-style view of medication changes over time | 3 days | Low | Helps visualize deprescribing progress |
| 8.5 | **Guided deprescribing workflow** — Step-by-step wizard: Review → Plan → Implement → Monitor → Follow up | 4 days | Medium | Reduces cognitive load; ensures consistent clinical process |
| 8.6 | **Patient-facing summary** — Simplified summary in plain language for patients/caregivers (health literacy optimized) | 2 days | High | Shared decision-making is a key principle of deprescribing |
| 8.7 | **One-click export** — Export to PDF, CSV, HTML, FHIR, C-CDA formats | 2 days | Medium | Interoperability with different workflows |
| 8.8 | **Onboarding tutorial** — Interactive walkthrough for first-time users | 2 days | Medium | Reduces support burden; improves feature discovery |
| 8.9 | **Keyboard shortcuts** — Efficiency shortcuts for power users | 1 day | Low | Clinicians value speed |
| 8.10 | **User feedback mechanism** — In-app feedback for AI recommendations (helpful / not helpful) to improve models | 2 days | Medium | Essential for continuous improvement |

---

## 9. EHR Integration

| # | Improvement | Effort | Priority | Rationale |
|---|-------------|--------|----------|-----------|
| 9.1 | **FHIR R4 API** — Standards-compliant FHIR endpoints (Patient, MedicationRequest, Condition, Observation, ClinicalImpression) | 10 days | **Critical** | FHIR is the universal EHR standard; required for any EHR integration |
| 9.2 | **SMART-on-FHIR app** — Enable launch from within EHR as a SMART-on-FHIR app | 5 days | High | Clinicians want CDSS within their existing EHR workflow |
| 9.3 | **Epic App Orchard / Cerner integration** — Certified integration with major EHR platforms | 15 days | High | Largest market share in US hospitals |
| 9.4 | **HL7 v2 interface** — Legacy HL7 v2 ADT (demographics) and ORM (medication order) message parsing | 5 days | Medium | Many hospitals still use HL7 v2 |
| 9.5 | **CDS Hooks** — Implement CDS Hooks specification for EHR-triggered clinical decision support | 3 days | High | Standards-based way to show recommendations within EHR workflows |
| 9.6 | **Bidirectional sync** — Sync deprescribing recommendations back to the EHR as clinical notes or order sets | 5 days | Medium | Reduces duplicate documentation |

---

## 10. Analytics & Population Health

| # | Improvement | Effort | Priority | Rationale |
|---|-------------|--------|----------|-----------|
| 10.1 | **Population dashboard** — Aggregate view of all patients with PIM counts, ACB scores, common drug classes, deprescribing progress | 5 days | High | Population health management is a key value proposition |
| 10.2 | **Quality measures reporting** — Generate CMS/NCQA quality measure reports (e.g., PQA measure PD-01: Use of High-Risk Medications in Older Adults) | 4 days | High | Directly ties to reimbursement (e.g., Medicare Star Ratings) |
| 10.3 | **Deprescribing success tracking** — Track which recommendations were accepted, implemented, and outcomes | 5 days | Medium | Measures system effectiveness; generates evidence for ROI |
| 10.4 | **Cost savings calculator** — Estimate medication cost reduction from deprescribing interventions | 3 days | Medium | Compelling value proposition for healthcare administrators |
| 10.5 | **Trend analysis** — Identify medication prescribing trends over time across the organization | 3 days | Low | Helps identify department-level prescribing patterns |
| 10.6 | **Benchmarking** — Compare facility against national/regional deprescribing benchmarks | 4 days | Low | Competitive differentiation |

---

## 11. Internationalization & Localization

| # | Improvement | Effort | Priority | Rationale |
|---|-------------|--------|----------|-----------|
| 11.1 | **International drug databases** — Support for non-US formularies (e.g., UK BNF, Australian PBS, Indian NLEM) | 10 days | High | Opens global markets; clinical criteria vary by country |
| 11.2 | **Localized clinical criteria** — Country-specific versions of Beers (US), STOPP/START (EU), and other criteria | 5 days | High | Clinical practice guidelines are jurisdiction-dependent |
| 11.3 | **Multi-language UI** — i18n framework (react-i18next) with translations for target markets (Spanish, French, German, Hindi, Arabic, Japanese) | 5 days | Medium | Non-English markets have huge demand for CDSS tools |
| 11.4 | **Locale-specific number/date formatting** — Proper formatting for all supported locales | 1 day | Medium | Professional appearance in target markets |

---

## 12. Performance & Scalability

| # | Improvement | Effort | Priority | Rationale |
|---|-------------|--------|----------|-----------|
| 12.1 | **Database indexing** — Proper indexes on frequently queried columns (drug_name, drug_class, medication_id) | 1 day | Medium | Current in-memory CSV lookup won't scale beyond prototype |
| 12.2 | **API response pagination** — Paginate list endpoints (medications, herbs, patients) | 1 day | Medium | Prevents overwhelming clients with large datasets |
| 12.3 | **Autoscaling configuration** — Configure horizontal pod autoscaling based on CPU/memory/request count | 2 days | Medium | Handles traffic spikes without over-provisioning |
| 12.4 | **CDN for static assets** — Serve frontend build from CloudFront/Cloudflare CDN | 1 day | Medium | Reduced latency for geographically distributed users |
| 12.5 | **Database read replicas** — Read replicas for analytics queries that don't need real-time data | 2 days | Low | Isolates analytics workload from production traffic |
| 12.6 | **GraphQL API** — Consider GraphQL for flexible client queries vs. REST's fixed response shapes | 5 days | Low | More efficient for complex nested data (patient + medications + analyses) |

---

## Priority Matrix

```
                    HIGH IMPACT                  MEDIUM IMPACT                    LOW IMPACT
                 ┌─────────────────┬─────────────────────────────────┬──────────────────────────────┐
  LOW EFFORT     │ 1.1, 1.4, 2.10  │ 1.8, 2.4, 2.5, 2.7, 5.9       │ 3.8, 7.4, 11.4               │
  (≤2 days)      │ 5.1, 5.2, 5.3   │                                 │                              │
                 │ 5.5, 5.10, 12.2 │                                 │                              │
                 └─────────────────┴─────────────────────────────────┴──────────────────────────────┘
                 ┌─────────────────┬─────────────────────────────────┬──────────────────────────────┐
  MEDIUM EFFORT  │ 2.1, 2.11, 4.1  │ 3.3, 3.10, 4.3, 4.4, 4.5,     │ 3.5, 3.7, 6.2, 6.3, 9.4      │
  (3-7 days)     │ 7.1, 7.2, 7.3   │ 4.8, 5.4, 5.6, 6.1, 7.7,     │ 11.1, 11.3                    │
                 │ 9.1, 9.2, 9.5   │ 8.1, 8.6, 9.3, 10.1, 10.2    │                              │
                 └─────────────────┴─────────────────────────────────┴──────────────────────────────┘
                 ┌─────────────────┬─────────────────────────────────┬──────────────────────────────┐
  HIGH EFFORT    │ 1.5, 1.6, 1.7   │ 3.4, 4.9, 8.5, 9.6, 10.3      │ 3.6, 6.5, 8.4, 11.2, 12.6    │
  (>7 days)      │ 2.2, 2.3, 5.7   │ 10.4, 12.1, 12.3, 12.4        │                              │
                 └─────────────────┴─────────────────────────────────┴──────────────────────────────┘
```

### Recommended Phasing

#### Phase 1 — Foundation (Weeks 1-2)
**Goal:** Secure, deployable, and testable

- Infrastructure (1.1, 1.4, 1.6)
- Authentication & RBAC (5.1, 5.2)
- HIPAA framework (5.3, 5.5, 5.10)
- Audit logging (2.10)
- Test suite (2.1)

#### Phase 2 — Core Product (Weeks 3-6)
**Goal:** Feature-complete, clinical depth

- Database migration (1.5)
- Drug database expansion (4.1, 4.2)
- DDI + disease-drug checking (4.3, 4.4)
- Renal dosing engine (4.5)
- Patient dashboard (8.1)
- FHIR API (9.1)

#### Phase 3 — Go-to-Market (Weeks 7-10)
**Goal:** Revenue-ready

- Billing integration (7.1, 7.2)
- Multi-tenant architecture (7.3)
- CI/CD (1.2)
- TypeScript migration (3.3)
- E2E tests (3.10)
- Landing page + signup flow (7.5)
- CDS Hooks integration (9.5)

#### Phase 4 — Scale (Weeks 11-16)
**Goal:** Enterprise-grade

- Local ML model (6.1) — cost reduction and PHI safety
- Population dashboard (10.1)
- Quality measures reporting (10.2)
- SMART-on-FHIR (9.2)
- International drug databases (11.1)
- Background task processing (2.2)
- i18n framework (11.3)

---

## Quick Wins (Can be done in 1-2 days each)

These improvements have high impact relative to effort and can be implemented immediately:

1. ✅ **Dockerfile + docker-compose** — Containerize the application
2. ✅ **Environment configuration** — Proper .env management with validation
3. ✅ **API versioning** — Prefix with `/v1/`
4. ✅ **Structured logging** — Replace `print()` with Loguru
5. ✅ **Rate limiting** — Prevent API abuse
6. ✅ **Security headers** — CSP, HSTS, etc.
7. ✅ **Error tracking** — Sentry integration
8. ✅ **Input validation** — Clinical range validators
9. ✅ **Pagination** — List endpoint pagination
10. ✅ **Drug-allergy checking** — Basic but valuable safety feature

---

## Clinical Accuracy & Safety

The following improvements directly impact clinical safety and are considered **non-negotiable** for production use:

- [ ] **Clinical validation study** — Compare system recommendations against a panel of geriatric pharmacists for accuracy
- [ ] **False positive/negative analysis** — Measure sensitivity and specificity of each engine
- [ ] **User override tracking** — Log when clinicians override system recommendations; analyze patterns to improve models
- [ ] **Clinical advisory board** — Establish a board of geriatricians and clinical pharmacists to guide development
- [ ] **Regular guideline updates** — Automated process to check for and incorporate new Beers/STOPP/START releases
- [ ] **FDA Adverse Event Reporting** — Cross-reference with FAERS for drug safety signals

---

*This roadmap is a living document. Prioritization should be revisited quarterly based on user feedback, market demands, and regulatory changes. For questions or suggestions, please open a GitHub Discussion or issue.*
